验证HAV生物标志物2A用于多重血清学鉴别甲型肝炎感染与疫苗接种者
研究以重组表达的HAV非结构蛋白2A作为生物标志物,在381份参考血清中建立多重血清学检测,区分既往HAV感染与疫苗接种者。HAV多重血清学检测抗HAV IgG/IgM阳性者的敏感性为99%、特异性为95%;2A生物标志物鉴别既往感染与疫苗接种者的准确率为92%。作者认为2A可用于疫情调查、人群纵向研究和免疫规划评估。
要点
- HAV多重血清学检测抗HAV IgG/IgM阳性者敏感性99%、特异性95%。
- HAV生物标志物2A鉴别既往感染与疫苗接种者的准确率为92%。
- 2A生物标志物可为疫情调查和免疫规划评估提供信息。
核心结论
- HAV生物标志物2A可用于区分既往HAV疫苗接种者与自然感染者。
- 在多重血清学方法中,该检测可为疫情调查、人群纵向研究和免疫规划评估提供有价值的新信息。
研究设计与样本
- 将HAV抗原以谷胱甘肽S转移酶(GST)融合蛋白形式重组表达,经谷胱甘肽标记的磁性荧光珠(Luminex®)亲和纯化后用于多重血清学检测。
- 使用381份参考血清验证多重HAV检测,血清免疫状态(HAV阴性、疫苗接种或感染)通过Abbott ARCHITECT® HAVAb-IgM或IgG、Abnova商业HAV ELISA及疫苗接种卡记录确定。
主要发现
- HAV多重血清学检测抗HAV IgG/IgM阳性个体的敏感性为99%,特异性为95%。
- HAV生物标志物2A可区分既往感染与疫苗接种个体,鉴别准确率为92%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Worldwide about 1.5 million clinical cases of hepatitis A virus (HAV) infections occur every year and increasingly countries are introducing HAV vaccination into the childhood immunization schedule with a single dose instead of the originally licenced two dose regimen. Diagnosis of acute HAV infection is determined serologically by anti-HAV-IgM detection using ELISA. Additionally anti-HAV-IgG can become positive during the early phase of symptoms, but remains detectable after infection and also after vaccination against HAV. Currently no serological marker allows the differentiation of HAV vaccinated individuals and those with a past infection with HAV. Such differentiation would greatly improve evaluation of vaccination campaigns and risk assessment of HAV outbreaks. Here we tested the HAV non-structural protein 2A, important for the capsid assembly, as a biomarker for the differentiation of the immune status in previously infected and vaccinated individuals. METHODS: HAV antigens were recombinantly expressed as glutathione-S-transferase (GST) fusion proteins. Using glutathione tagged, magnetic fluorescent beads (Luminex®), the proteins were affinity purified and used in a multiplex serological assay. The multiplex HAV assay was validated using 381 reference sera in which the immune status HAV negative, vaccinated or infected was established using the Abbott ARCHITECT® HAVAb-IgM or IgG, the commercial HAV ELISA from Abnova and documentation in vaccination cards. RESULTS: HAV multiplex serology showed a sensitivity of 99% and specificity of 95% to detect anti-HAV IgG/IgM positive individuals. HAV biomarker 2A allowed the differentiation between previously infected and vaccinated individuals. HAV vaccinated individuals and previously infected individuals could be identified with 92% accuracy. CONCLUSION: HAV biomarker 2A can be used to differentiate between previously HAV-vaccinated and naturally infected individuals. Within a multiplex serological approach this assay can provide valuable novel information in the context of outbreak investigations, longitudinal population based studies and evaluations of immunization campaigns.
引用
- Bohm K, Filomena A, Schneiderhan-Marra N, et al. Validation of HAV biomarker 2A for differential diagnostic of hepatitis A infected and vaccinated individuals using multiplex serology. Vaccine. 2017. PMID: 28919226. doi:10.1016/j.vaccine.2017.08.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。